Anlotinib: all 260 studies that test it

Page 3 of 3. Open to participants first (104), then studies with results posted, then the rest; newest registration first within each.

• Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant MelanomaStatus unknownNCT03991975Phase 1/2
• Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung CancerStatus unknownNCT03983928Phase 1/2
• Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 AntibodyStatus unknownNCT03975036Phase 2/3
• Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic SarcomaStatus unknownNCT03946943Phase 2
• Anlotinib in Advanced Solid Tumors With FGFR AlterationStatus unknownNCT03929965Not applicable
• Anlotinib for Patients With Platinum Resistant or Refractory Ovarian CancerStatus unknownNCT03924882Phase 2
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）Status unknownNCT03910127Phase 1
• Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line TherapyCompletedNCT03906058Phase 2
• Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid TumorsStatus unknownNCT03897283Phase 1
• Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue SarcomaStatus unknownNCT03880695Phase 2
• Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung CancerStatus unknownNCT03841136Phase 2
• A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular CarcinomaStatus unknownNCT03825705Phase 1/2
• S1 Plus Anlotinib in Treating Patients With Refractory or Relapsed Small-cell Lung CancerCompletedNCT03823118Phase 2
• Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma PatientsStatus unknownNCT03815474Phase 2
• Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLCStatus unknownNCT03799601Phase 4
• Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive ChemotherapyStatus unknownNCT03792542Phase 2
• Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLCStatus unknownNCT03778138Phase 2
• Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLCStatus unknownNCT03769805Not applicable
• Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLCStatus unknownNCT03768037Phase 4
• Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03766776Not applicable
• Study of Anlotinib in Non-squamous NSCLC Patients Who Failed First-Line（ALTER-L020）Status unknownNCT03755869Phase 4
• Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029）CompletedNCT03743129Phase 2
• Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLCCompletedNCT03736837Phase 2
• Anlotinib in Treatment of Recurrent Small Cell Lung CancerStatus unknownNCT03732846Phase 2
• Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung AdenocarcinomaStatus unknownNCT03728374Phase 2
• EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLCStatus unknownNCT03720873Phase 2
• Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLCStatus unknownNCT03706287Phase 1/2
• Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC PatientsStatus unknownNCT03672136Phase 2
• Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and CisplatinStatus unknownNCT03671538Not applicable
• Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLCStatus unknownNCT03654027Phase 2
• Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal CarcinomaStatus unknownNCT03639467Phase 1/2
• Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung CancerStatus unknownNCT03624309Phase 2
• Anlotinib for Advanced and Refractory Natural Killer /T-cell LymphomaCompletedNCT03618238Phase 2
• Phase I Study of the Combination of Anlotinib With GefitinibStatus unknownNCT03602027Not applicable
• A Study of Anlotinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT03591666Phase 2
• Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT03589950Phase 2
• Study of Anlotinib in Patients With Primary Malignant Bone TumorsStatus unknownNCT03527888Phase 2
• A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3Status unknownNCT03457844Phase 2
• Anlotinib and Irinotecan for Ewing SarcomaStatus unknownNCT03416517Phase 1/2
• Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell CarcinomaStatus unknownNCT03387904Phase 2
• Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)CompletedNCT03059797Phase 2
• A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer PatientsCompletedNCT02825563Phase 1
• A Study of Anlotinib in Patients With Hepatocellular CarcinomaStatus unknownNCT02809534Phase 2
• A Phase I Additional Study of Anlotinib on Tolerance and PharmacokineticsStatus unknownNCT02752516Phase 1
• Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Phase 2
• Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)CompletedNCT02586350Phase 2/3
• Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)Status unknownNCT02586337Phase 2/3
• Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)Active, not recruitingNCT02584478Phase 3
• Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)TerminatedNCT02558348Phase 1/2
• Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Phase 2/3
• Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)Status unknownNCT02449343Phase 2/3
• Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）CompletedNCT02388919Phase 2/3
• Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)CompletedNCT02332499Phase 2/3
• Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs TherapyStatus unknownNCT02072044Phase 2
• Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）Status unknownNCT02072031Phase 2
• To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung CancerStatus unknownNCT02029209Phase 2/3
• Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）CompletedNCT01924195Phase 2
• A Phase II Study of Anlotinib in STS PatientsCompletedNCT01878448Phase 2
• A Phase II Study of Anlotinib in MTC PatientsCompletedNCT01874873Phase 2
• A Phase I Study of Anlotinib on Tolerance and PharmacokineticsCompletedNCT01833923Phase 1

← Anlotinib overview